|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/09/23 Helius Medical Technologies, Inc. 10-K 12/31/22 76:7.8M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.87M
2: EX-21.1 Subsidiaries List HTML 22K
3: EX-23.1 Consent of Expert or Counsel HTML 21K
4: EX-23.2 Consent of Expert or Counsel HTML 21K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
13: R1 Document and Entity Information HTML 92K
14: R2 Consolidated Balance Sheets HTML 123K
15: R3 Consolidated Balance Sheets (Parenthetical) HTML 38K
16: R4 Consolidated Statements of Operations and HTML 133K
Comprehensive Loss
17: R5 Consolidated Statements of Stockholders' Equity HTML 91K
18: R6 Consolidated Statements of Cash Flows HTML 123K
19: R7 Description of Business HTML 27K
20: R8 Significant Accounting Policies HTML 40K
21: R9 Goodwill Impairment HTML 24K
22: R10 Supplemental Balance Sheet Disclosures HTML 83K
23: R11 Leases HTML 35K
24: R12 Intangible Assets HTML 70K
25: R13 Fair Value Measurements HTML 27K
26: R14 Common Stock and Warrants HTML 64K
27: R15 Stock-Based Compensation HTML 102K
28: R16 Basic and Diluted Loss Per Share HTML 55K
29: R17 Income Taxes HTML 122K
30: R18 Defined Contribution Plan HTML 24K
31: R19 Commitments and Contingencies HTML 24K
32: R20 Enterprise-Wide Disclosures HTML 42K
33: R21 Significant Accounting Policies (Policies) HTML 96K
34: R22 Supplemental Balance Sheet Disclosures (Tables) HTML 85K
35: R23 Leases (Tables) HTML 34K
36: R24 Intangible Assets (Tables) HTML 72K
37: R25 Common Stock and Warrants (Tables) HTML 53K
38: R26 Stock-Based Compensation (Tables) HTML 101K
39: R27 Basic and Diluted Loss Per Share (Tables) HTML 56K
40: R28 Income Taxes (Tables) HTML 125K
41: R29 Enterprise-Wide Disclosures (Tables) HTML 37K
42: R30 Description of Business (Details) HTML 36K
43: R31 SIGNIFICANT ACCOUNTING POLICIES - Additional HTML 34K
Information (Details)
44: R32 Goodwill Impairment (Details) HTML 26K
45: R33 SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Accounts HTML 30K
receivable, net (Details)
46: R34 SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory HTML 35K
(Details)
47: R35 SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Prepaid HTML 27K
expenses and other current assets (Details)
48: R36 SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property HTML 35K
and equipment, net (Details)
49: R37 SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Accrued HTML 36K
Expenses (Details)
50: R38 SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Deferred HTML 47K
Revenue (Details)
51: R39 Leases (Details) HTML 48K
52: R40 INTANGIBLE ASSETS - Summary (Details) HTML 39K
53: R41 INTANGIBLE ASSETS - Estimated Amortization Expense HTML 28K
(Details)
54: R42 COMMON STOCK AND WARRANTS - Additional Information HTML 107K
(Details)
55: R43 COMMON STOCK AND WARRANTS - Summary of Weighted HTML 70K
Average Assumptions Used in Estimating Fair Value
of Warrants (Details)
56: R44 COMMON STOCK AND WARRANTS - Summary of Warrant HTML 39K
Activity (Details)
57: R45 STOCK-BASED COMPENSATION - Additional Information- HTML 67K
(Details)
58: R46 STOCK-BASED COMPENSATION - Fair Value Assumptions HTML 33K
(Details)
59: R47 STOCK-BASED COMPENSATION - Summary of Company's HTML 48K
Stock Option Activity (Details)
60: R48 STOCK-BASED COMPENSATION - Other Awards (Details) HTML 38K
61: R49 STOCK-BASED COMPENSATION - Stock-Based HTML 30K
Compensation Expense (Details)
62: R50 Basic and Diluted Loss Per Share (Details) HTML 50K
63: R51 Basic and Diluted Loss Per Share - Antidilutive HTML 30K
Securities (Details)
64: R52 INCOME TAXES - Components of Net Loss for Income HTML 31K
Tax (Details)
65: R53 INCOME TAXES - Reconciliation of Income Tax HTML 47K
Provision Computed at Statutory Rates (Details)
66: R54 INCOME TAXES - Components of Deferred Income Tax HTML 60K
Assets and Liabilities (Details)
67: R55 INCOME TAXES - Net operating losses (Details) HTML 46K
68: R56 INCOME TAXES - Tax credit carryforward (Details) HTML 37K
69: R57 Defined Contribution Plan (Details) HTML 30K
70: R58 COMMITMENTS AND CONTINGENCIES - Additional HTML 27K
Information (Details)
71: R59 Enterprise-Wide Disclosures (Details) HTML 52K
74: XML IDEA XML File -- Filing Summary XML 135K
72: XML XBRL Instance -- hsdt-20221231x10k_htm XML 1.59M
73: EXCEL IDEA Workbook of Financial Reports XLSX 124K
9: EX-101.CAL XBRL Calculations -- hsdt-20221231_cal XML 190K
10: EX-101.DEF XBRL Definitions -- hsdt-20221231_def XML 474K
11: EX-101.LAB XBRL Labels -- hsdt-20221231_lab XML 1.36M
12: EX-101.PRE XBRL Presentations -- hsdt-20221231_pre XML 930K
8: EX-101.SCH XBRL Schema -- hsdt-20221231 XSD 160K
75: JSON XBRL Instance as JSON Data -- MetaLinks 423± 675K
76: ZIP XBRL Zipped Folder -- 0001558370-23-003338-xbrl Zip 448K
Exhibit 31.1
Certification of Chief Executive Officer
of Periodic Report Pursuant to Rule 13a-14(a) and Rule 15d-14(a)
I, Dane C. Andreeff, certify that:
1. | I have reviewed this annual report on Form 10-K of Helius Medical Technologies, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
| |
Date: March 9, 2023 | |
| |
/s/ Dane C. Andreeff | |
| |
President and Chief Executive Officer | |
(Principal Executive Officer) | |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/9/23 | 8-K | ||
| For Period end: | 12/31/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/23/23 Helius Medical Technologies, Inc. 424B5 1:387K Toppan Merrill/FA 5/25/23 Helius Medical Technologies, Inc. S-3/A 3:378K Toppan Merrill/FA 3/10/23 Helius Medical Technologies, Inc. S-3 9:1.1M Toppan Merrill/FA |